Published in Cancer Res on April 15, 2001
The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev (2007) 6.77
methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biol (2012) 3.44
DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet (2012) 3.33
Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci U S A (2007) 2.91
Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn (2008) 2.71
Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res (2007) 2.69
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46
Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol (2003) 2.42
GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol (2003) 2.42
The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. Nucleic Acids Res (2003) 2.41
Tumour class prediction and discovery by microarray-based DNA methylation analysis. Nucleic Acids Res (2002) 2.34
Predicting aberrant CpG island methylation. Proc Natl Acad Sci U S A (2003) 2.25
Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J (2003) 2.21
CpGcluster: a distance-based algorithm for CpG-island detection. BMC Bioinformatics (2006) 2.19
A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med (2006) 2.16
A DNA methylation fingerprint of 1628 human samples. Genome Res (2011) 2.16
High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci U S A (2007) 2.10
DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res (2008) 2.08
Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc Natl Acad Sci U S A (2003) 2.07
Epigenetics and human disease: translating basic biology into clinical applications. CMAJ (2006) 1.98
Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res (2010) 1.97
Cancer epigenetics: linking basic biology to clinical medicine. Cell Res (2011) 1.88
Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer. Proc Natl Acad Sci U S A (2011) 1.82
Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene (2004) 1.81
Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. Oncogene (2008) 1.81
Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res (2006) 1.80
Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am J Pathol (2003) 1.79
DNA methylation in hepatocellular carcinoma. World J Gastroenterol (2008) 1.77
Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer (2006) 1.77
Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev (2009) 1.76
Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer (2003) 1.73
The invasion front of human colorectal adenocarcinomas shows co-localization of nuclear beta-catenin, cyclin D1, and p16INK4A and is a region of low proliferation. Am J Pathol (2001) 1.73
A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines. Mol Cancer (2004) 1.72
SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis. Br J Cancer (2008) 1.70
Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res (2008) 1.70
Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol (2002) 1.68
Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch (2009) 1.67
p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev (2010) 1.66
Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes Dev (2001) 1.63
A real-time PCR assay for DNA-methylation using methylation-specific blockers. Nucleic Acids Res (2004) 1.63
State of the science: an update on renal cell carcinoma. Mol Cancer Res (2012) 1.58
Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. Am J Respir Cell Mol Biol (2008) 1.58
Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol (2004) 1.58
Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia (2010) 1.58
Epigenetic regulation of CD44 in Hodgkin and non-Hodgkin lymphoma. BMC Cancer (2010) 1.55
DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer (2008) 1.55
Methylation target array for rapid analysis of CpG island hypermethylation in multiple tissue genomes. Am J Pathol (2003) 1.51
Differential effects of p19(Arf) and p16(Ink4a) loss on senescence of murine bone marrow-derived preB cells and macrophages. Proc Natl Acad Sci U S A (2001) 1.51
Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer. Biochemistry (2011) 1.48
Promoter methylation status of E-cadherin, hMLH1, and p16 genes in nonneoplastic gastric epithelia. Am J Pathol (2002) 1.48
Analysis and accurate quantification of CpG methylation by MALDI mass spectrometry. Nucleic Acids Res (2003) 1.46
New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res (2010) 1.46
Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor. World J Gastroenterol (2006) 1.45
ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and glioma. BMC Cancer (2009) 1.44
Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol Biomarkers Prev (2009) 1.43
Retracted Aberrant methylation of SPARC in human lung cancers. Br J Cancer (2005) 1.40
DNA Electrochemistry Shows DNMT1 Methyltransferase Hyperactivity in Colorectal Tumors. Chem Biol (2015) 1.39
Methylation mediated silencing of TMS1/ASC gene in prostate cancer. Mol Cancer (2006) 1.38
Combination of methylated-DNA precipitation and methylation-sensitive restriction enzymes (COMPARE-MS) for the rapid, sensitive and quantitative detection of DNA methylation. Nucleic Acids Res (2006) 1.36
Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch (2010) 1.34
MeInfoText: associated gene methylation and cancer information from text mining. BMC Bioinformatics (2008) 1.34
Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer (2006) 1.34
Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer (2006) 1.32
The presence of RNA polymerase II, active or stalled, predicts epigenetic fate of promoter CpG islands. Genome Res (2009) 1.32
DNA methylation based biomarkers in non-invasive cancer screening. Curr Mol Med (2010) 1.32
Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.30
Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol (2010) 1.29
Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. Am J Pathol (2002) 1.29
Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis. Cancer Res (2007) 1.29
CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells. PLoS Genet (2007) 1.28
Proteins that bind methylated DNA and human cancer: reading the wrong words. Br J Cancer (2008) 1.27
The expression and clinical significance of DNA methyltransferase proteins in human gastric cancer. Dig Dis Sci (2008) 1.24
A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. J Clin Invest (2003) 1.23
Epigenomics and breast cancer. Pharmacogenomics (2008) 1.23
MicroRNA alterations and associated aberrant DNA methylation patterns across multiple sample types in oral squamous cell carcinoma. PLoS One (2011) 1.23
Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review. Int J Cancer (2011) 1.20
The context and potential of epigenetics in oncology. Br J Cancer (2009) 1.20
Genetic and epigenetic silencing of the beclin 1 gene in sporadic breast tumors. BMC Cancer (2010) 1.20
Detection and quantification of methylation in DNA using solid-state nanopores. Sci Rep (2013) 1.19
Capillary electrophoretic analysis of genomic DNA methylation levels. Nucleic Acids Res (2003) 1.19
Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer. BMC Cancer (2009) 1.19
Critical role for transcription factor C/EBP-beta in regulating the expression of death-associated protein kinase 1. Mol Cell Biol (2008) 1.19
Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res (2010) 1.18
DNA methylation and cancer diagnosis. Int J Mol Sci (2013) 1.18
LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics (2009) 1.17
Second-hand smoke and human lung cancer. Lancet Oncol (2008) 1.17
Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells. Mol Cancer Ther (2010) 1.16
Highly individual methylation patterns of alternative glucocorticoid receptor promoters suggest individualized epigenetic regulatory mechanisms. Nucleic Acids Res (2008) 1.16
Hypermethylation of the TPEF/HPP1 gene in primary and metastatic colorectal cancers. Neoplasia (2005) 1.15
DNA methylation data analysis and its application to cancer research. Epigenomics (2013) 1.14
Epigenetic disruption of cadherin-11 in human cancer metastasis. J Pathol (2012) 1.14
Characteristic promoter hypermethylation signatures in male germ cell tumors. Mol Cancer (2002) 1.13
Hypoxia-induced epigenetic regulation and silencing of the BRCA1 promoter. Mol Cell Biol (2011) 1.13
Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors. Oncogene (2007) 1.13
Colorectal cancer "methylator phenotype": fact or artifact? Neoplasia (2005) 1.13
Complex epigenetic regulation of engrailed-2 (EN-2) homeobox gene in the autism cerebellum. Transl Psychiatry (2013) 1.12
Prediction of CpG-island function: CpG clustering vs. sliding-window methods. BMC Genomics (2010) 1.12
Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br J Cancer (2007) 1.12
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A (1996) 29.54
CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A (1999) 13.02
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med (2000) 12.34
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet (1999) 9.53
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med (1995) 9.10
Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res (1998) 8.95
Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet (1994) 8.34
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res (1995) 7.42
DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet (2000) 6.57
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 6.38
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res (1999) 6.10
DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet (2000) 5.72
E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res (1995) 5.11
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature (2001) 4.99
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res (1997) 4.73
Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res (1998) 4.39
Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet (2001) 3.96
Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A (1998) 3.80
SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet (2001) 3.76
Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res (2000) 3.65
Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res (1996) 3.50
Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res (1999) 3.48
Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. J Biol Chem (2001) 3.23
Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res (1994) 3.18
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res (1997) 3.17
Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res (1999) 3.15
Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res (1997) 3.09
Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res (2000) 2.99
Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem (2000) 2.97
CpG methylation is maintained in human cancer cells lacking DNMT1. Nature (2000) 2.94
Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res (2001) 2.79
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res (2000) 2.79
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene (2013) 2.64
Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res (1999) 2.62
Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood (1999) 2.57
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet (2001) 2.50
Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res (2001) 2.50
K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol (2001) 2.48
p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med (1995) 2.47
Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst (1999) 2.34
Methylation-specific PCR simplifies imprinting analysis. Nat Genet (1997) 2.33
An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature (1997) 2.29
Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem (1997) 2.27
De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5-)-methyltransferase. Mol Cell Biol (1996) 2.26
DNA methylation, chromatin inheritance, and cancer. Oncogene (2001) 2.26
Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. Cancer Res (2000) 2.18
Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res (1999) 2.17
The short arm of chromosome 11 is a "hot spot" for hypermethylation in human neoplasia. Proc Natl Acad Sci U S A (1988) 2.14
Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer (2008) 2.13
Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res (1997) 2.12
Isolation and characterization of the cDNA encoding human DNA methyltransferase. Nucleic Acids Res (1992) 2.10
Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res (1980) 2.10
Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res (1999) 2.09
High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. Proc Natl Acad Sci U S A (1991) 2.07
Conservation of the Drosophila lateral inhibition pathway in human lung cancer: a hairy-related protein (HES-1) directly represses achaete-scute homolog-1 expression. Proc Natl Acad Sci U S A (1997) 2.00
MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene (1998) 1.99
Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proc Natl Acad Sci U S A (1996) 1.99
Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors. Proc Natl Acad Sci U S A (1993) 1.97
Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res (2001) 1.97
Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res (2000) 1.95
Increased cytosine DNA-methyltransferase activity during colon cancer progression. J Natl Cancer Inst (1993) 1.94
Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res (2000) 1.91
Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res (1998) 1.91
Expression of an exogenous eukaryotic DNA methyltransferase gene induces transformation of NIH 3T3 cells. Proc Natl Acad Sci U S A (1993) 1.86
Molecular markers of neuroendocrine development and evidence of environmental regulation. Proc Natl Acad Sci U S A (1987) 1.84
Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome. Oncogene (2000) 1.83
Mutation affecting the 12th amino acid of the c-Ha-ras oncogene product occurs infrequently in human cancer. Science (1983) 1.83
Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res (1995) 1.82
Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol (2010) 1.81
Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res (1998) 1.81